GU Cancers Symposium 2013 - Real-world experience with sipuleucel-T in metastatic castration-resistant prostate cancer patients ≥ 80 years-old: Data from PROCEED, by A. Oliver Sartor, MD, et al. - Poster

ORLANDO, FL, USA (UroToday.com) - Sipuleucel-T is an autologous cellular immunotherapy approved for the treatment of men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)...Click here to enlarge and view the poster.

  

PROCEED elderly thumb
                              (Click thumbnail to enlarge poster)

 

Presented by Chadi Nabhan, MD,1 Oliver Sartor, MD,2 Matthew Cooperberg, MD,3 Jeffrey Vacirca, MD,4 Raoul Concepcion, MD,5 William Berry, MD,6 Manish Dhawan, MD,7 Ronald Tutrone, MD,8 Andrew Sandler, MD,9 Candice McCoy, MD,9 James Whitmore, PhD,9 Robert Tyler, PhD,9 and Celestia Higano, MD10 at the 2013 Genitourinary Cancers Symposium - February 14 - 16, 2013 - Rosen Shingle Creek - Orlando, Florida USA

1Advocate Lutheran General Hospital, Park Ridge, IL; 2Tulane University School of Medicine, New Orleans, LA; 3UCSF School of Medicine, San Francisco, CA; 4North Shore Hematology Oncology Associates, East Setauket, NY; 5Urology Associates, Nashville, TN; 6US Oncology, Raleigh, NC 7Highland Clinic, Shreveport, LA; 8Chesapeake Urology Research Associates, Baltimore, MD; 9Dendreon, Corp., Seattle, WA; 10University of Washington, Seattle, WA

Click here to view session highlights by a UroToday.com medical editor



gucancerssympalt



View Full 2013 GU Cancers Symposium Coverage



  

 

 

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe